Related Experiment Video
Updated: Jun 20, 2026
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
TFPI2 promotes NK cell-mediated glioblastoma killing through adhesion and checkpoint control
Dongpeng Zheng1,2,3,4, Fengqi Li1,2,4, Zhuang Zhang1,4
1School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin 300072, China.
Abstract:
Immune-mediated killing triggers dynamic transcriptional adaptations in tumor cells that can reciprocally regulate the cytolytic process. Unraveling such feedback mechanisms is crucial for advancing cancer immunotherapy. Here, we identified tissue factor pathway inhibitor 2 (TFPI2) as a central node in natural killer (NK)-glioblastoma cross talk. Using transcriptomic and functional approaches, we demonstrated that NK cell attack induces TFPI2 expression in glioblastoma cells via IL1β- and TNFα-driven activation of NFκB signaling. TFPI2 not only restrains tumor proliferation by suppressing the POU2F2-CCND1 axis but also enhances NK cytotoxicity through two complementary mechanisms: It supports optimal ICAM1 expression to promote NK-tumor adhesion, and it selectively represses the immune checkpoint molecule SIGLEC15, restoring NK cell effector function. In vivo, loss of TFPI2 accelerates glioblastoma progression and abrogates the efficacy of adoptive NK cell therapy in a context-dependent manner; the functionality is likely restricted to tumors retaining the capacity for TFPI2 induction upon inflammatory stimuli. Our findings identified the TFPI2-ICAM1 and TFPI2-SIGLEC15 axes as conditional regulators of immune-tumor adhesion and checkpoint control, supporting TFPI2 as a candidate therapeutic target for a subset of glioblastomas amenable to inflammatory reprogramming.
Insights
Tissue factor pathway inhibitor 2 (TFPI2) enhances natural killer (NK) cell glioblastoma immunotherapy by improving NK-tumor adhesion and reducing immune checkpoints. TFPI2 is a potential therapeutic target for specific glioblastomas.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tumor cells dynamically adapt transcriptionally to immune-mediated killing, influencing immunotherapy efficacy.
- Understanding these feedback loops is critical for advancing cancer immunotherapy strategies.
Purpose of the Study:
- To identify key molecular mediators of natural killer (NK) cell and glioblastoma cell interactions.
- To elucidate the mechanisms by which glioblastoma cells regulate NK cell cytotoxicity and tumor progression.
Main Methods:
- Transcriptomic analysis to identify key regulatory molecules.
- Functional assays to assess the impact of TFPI2 on glioblastoma proliferation and NK cell activity.
- In vivo studies using glioblastoma models to evaluate therapeutic potential.
Main Results:
- Tissue factor pathway inhibitor 2 (TFPI2) was identified as a central mediator in NK-glioblastoma cross talk.
- NK cell attack induces TFPI2 expression in glioblastoma cells via NFκB signaling.
- TFPI2 restrains glioblastoma proliferation and enhances NK cell cytotoxicity by promoting ICAM1 expression and repressing SIGLEC15.
Conclusions:
- TFPI2 acts as a critical regulator of immune-tumor adhesion and immune checkpoint control in glioblastoma.
- TFPI2 represents a promising therapeutic target for glioblastomas responsive to inflammatory reprogramming.
- Loss of TFPI2 accelerates glioblastoma progression and impairs adoptive NK cell therapy efficacy.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
01:27Tumor Immunotherapy